Why wait?

To start immune checkpoint inhibition for advanced non-small cell lung cancer (NSCLC). This inevitable (because durvalumab can’t expect to corner this market forever) phase 1 trial reports “tolerability” of adding pembro to upfront chemoradiation for stage III NSCLC, despite one case of grade 5 pneumonitis. | Jabbour, JAMA Oncol 2020